Satellos Bioscience (MSCL) Registration filing summary

Company overview and business model

• Clinical-stage drug development company focused on therapies for degenerative muscle diseases, initially Duchenne Muscular Dystrophy (DMD).

• Lead candidate SAT-3247 is an orally administered small molecule targeting muscle stem cell polarity, currently in two clinical trials (BASECAMP and TRAILHEAD).

• Proprietary MyoReGenX™ platform used to identify additional muscle diseases for future pipeline expansion.

• Operations span Canada, the US, and Australia, with subsidiaries in each region.

• Recent milestones include FDA Fast Track designation and positive interim clinical data for SAT-3247.

Financial performance and metrics

• As of March 31, 2026, cash and equivalents were $69.9 million, with working capital of $70.66 million.

• Net losses of $24.8 million (2025) and $20.6 million (2024); accumulated deficit of $81.9 million as of December 31, 2025.

• Management estimates current liquidity is sufficient to finance operations through 2027.

• Company anticipates continued losses and negative cash flows until product commercialization.

Use of proceeds and capital allocation

• Proceeds will fund ongoing R&D, working capital, advancing SAT-3247 through clinical trials, and investment in early-stage programs.

• Management retains broad discretion over allocation; actual use may vary based on operational needs and trial outcomes.

• No specific allocation or pending transactions as of the filing date.